Found: 119
Select item for more details and to access through your institution.
Assessment of the activity of ceftaroline against clinical isolates of penicillin-intermediate and penicillin-resistant Streptococcus pneumoniae with elevated MICs of ceftaroline using an in vitro pharmacodynamic model.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2012, v. 67, n. 7, p. 1706, doi. 10.1093/jac/dks113
- By:
- Publication type:
- Article
Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus, heteroresistant vancomycin-intermediate S. aureus, vancomycin-intermediate S. aureus and vancomycin-resistant S. ...
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2011, v. 66, n. 6, p. 1301, doi. 10.1093/jac/dkr110
- By:
- Publication type:
- Article
Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum β-lactamases, AmpC β-lactamases and reduced susceptibility to carbapenems ...
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2009, v. 64, n. 4, p. 824, doi. 10.1093/jac/dkp254
- By:
- Publication type:
- Article
Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2009, v. 64, n. 2, p. 364, doi. 10.1093/jac/dkp176
- By:
- Publication type:
- Article
In vitro activity of the investigational ketolide cethromycin against macrolide- and penicillin-resistant Streptococcus pneumoniae: review of the 1998 to 2006 Canadian Respiratory Organism Susceptibility Study (CROSS).
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2009, v. 63, n. 3, p. 620
- By:
- Publication type:
- Article
In vitro activity of ceftobiprole against clinical isolates of Pseudomonas aeruginosa obtained from Canadian intensive care unit (ICU) patients as part of the CAN-ICU Study.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2008, v. 62, n. 1, p. 206
- By:
- Publication type:
- Article
In vitro antibacterial activity of the peptide deformylase inhibitor BB-83698.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2004, v. 53, n. 4, p. 664, doi. 10.1093/jac/dkh129
- By:
- Publication type:
- Article
Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001.
- Published in:
- 2003
- By:
- Publication type:
- journal article
Importance of using current NCCLS breakpoints to interpret cefotaxime and ceftriaxone MICs for Streptococcus pneumoniae.
- Published in:
- 2003
- By:
- Publication type:
- commentary
Activity of faropenem, a new furanem, against European respiratory pathogens collected during 2000-2001: a comparison with other beta-lactam agents.
- Published in:
- 2003
- By:
- Publication type:
- research
Presence of ROB-1 β-lactamase correlates with cefaclor resistance among recent isolates of Haemophilus influenzae.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2000, v. 45, n. 6, p. 871, doi. 10.1093/jac/45.6.871
- By:
- Publication type:
- Article
Antibiotic resistance in respiratory tract isolates of Haemophilus influenzae and Moraxella catarrhalis collected from across Canada in 1997-1998.
- Published in:
- 2000
- By:
- Publication type:
- journal article
Recommendations for the calculation of the post-antibiotic effect for β-lactams and Gram-negative bacilli.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 1995, v. 35, n. 4, p. 551
- By:
- Publication type:
- Article
The accumulation of fluoroquinolones in Staphylococcus aureus during the postantibiotic effect.
- Published in:
- 1994
- By:
- Publication type:
- journal article
708. In Vitro Activity of Plazomicin vs. Clinical Isolates of Gram-Negative Bacilli, Including Aminoglycoside Nonsusceptible and Multidrug-Resistant Subsets, Recovered from Patients Across Canada as Part of the CANWARD study, 2011–2018.
- Published in:
- Open Forum Infectious Diseases, 2019, v. 6, p. S319, doi. 10.1093/ofid/ofz360.776
- By:
- Publication type:
- Article
598. In Vitro Activity of Aztreonam in Combination with Ceftazidime–Avibactam, Amoxicillin–Clavulanate, and Piperacillin–Tazobactam vs. NDM-Producing Escherichia coli and Klebsiella pneumoniae Clinical Isolates.
- Published in:
- Open Forum Infectious Diseases, 2019, v. 6, p. S281, doi. 10.1093/ofid/ofz360.667
- By:
- Publication type:
- Article
128. Adequacy of Commonly Prescribed Antimicrobials for Empiric Coverage of Gram-Negative Bacterial Pathogens Recovered from the Bloodstream of Patients Attending Emergency Rooms in Canada: Analysis of Data from the CANWARD Study, 2007 to 2018.
- Published in:
- Open Forum Infectious Diseases, 2019, v. 6, p. S93, doi. 10.1093/ofid/ofz360.203
- By:
- Publication type:
- Article
Hypermucoviscous Klebsiella Syndrome Without Liver Abscess in a Patient With Immunoglobulin G2 Immune Deficiency.
- Published in:
- Open Forum Infectious Diseases, 2014, v. 1, n. 2, p. 1, doi. 10.1093/ofid/ofu080
- By:
- Publication type:
- Article
In Vitro Activity of Imipenem/Relebactam Against Gram-Negative Bacilli from Pediatric Patients—Study for Monitoring Antimicrobial Resistance Trends (SMART) global surveillance program 2015–2017.
- Published in:
- Journal of the Pediatric Infectious Diseases Society, 2021, v. 10, n. 3, p. 274, doi. 10.1093/jpids/piaa056
- By:
- Publication type:
- Article
Ceftobiprole.
- Published in:
- American Journal of Clinical Dermatology, 2008, v. 9, n. 4, p. 245, doi. 10.2165/00128071-200809040-00004
- By:
- Publication type:
- Article
Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in Greece and Italy—SMART 2017–2021.
- Published in:
- European Journal of Clinical Microbiology & Infectious Diseases, 2024, v. 43, n. 7, p. 1343, doi. 10.1007/s10096-024-04756-4
- By:
- Publication type:
- Article
In vitro activity of aztreonam–avibactam against Enterobacterales isolates collected in Latin America, Africa/Middle East, Asia, and Eurasia for the ATLAS Global Surveillance Program in 2019–2021.
- Published in:
- European Journal of Clinical Microbiology & Infectious Diseases, 2023, v. 42, n. 9, p. 1135, doi. 10.1007/s10096-023-04645-2
- By:
- Publication type:
- Article
Factors Influencing Fluoroquinolone Resistance.
- Published in:
- 2003
- By:
- Publication type:
- Letter
Virulence characteristics and phylogenetic background of multidrug-resistant and antimicrobial-susceptible clinical isolates of Escherichia coli from across the United States, 2000-2001.
- Published in:
- 2004
- By:
- Publication type:
- journal article
Intravenous Fosfomycin: An Assessment of Its Potential for Use in the Treatment of Systemic Infections in Canada.
- Published in:
- Canadian Journal of Infectious Diseases & Medical Microbiology, 2018, p. 1, doi. 10.1155/2018/8912039
- By:
- Publication type:
- Article
Fidaxomicin: A novel agent for the treatment of Clostridium difficile infection.
- Published in:
- Canadian Journal of Infectious Diseases & Medical Microbiology, 2015, v. 26, n. 6, p. 305, doi. 10.1155/2015/934594
- By:
- Publication type:
- Article
In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in Latin America: SMART 2018‒2020.
- Published in:
- Brazilian Journal of Infectious Diseases, 2023, v. 27, n. 3, p. 1, doi. 10.1016/j.bjid.2023.102775
- By:
- Publication type:
- Article
Epidemiology and in vitro activity of ceftazidimeavibactam and comparator agents against multidrugresistant isolates of Enterobacterales and Pseudomonas aeruginosa collected in Latin America as part of the ATLAS surveillance program in 2015‒2020.
- Published in:
- Brazilian Journal of Infectious Diseases, 2023, v. 27, n. 3, p. 1, doi. 10.1016/j.bjid.2023.102759
- By:
- Publication type:
- Article
In vitro activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa isolates collected in Latin America as part of the ATLAS global surveillance program, 2017-2019.
- Published in:
- Brazilian Journal of Infectious Diseases, 2021, v. 25, n. 6, p. 1, doi. 10.1016/j.bjid.2021.101647
- By:
- Publication type:
- Article
Resistance among Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Latin American countries: SMART 2013-2015.
- Published in:
- Brazilian Journal of Infectious Diseases, 2017, v. 21, n. 3, p. 343, doi. 10.1016/j.bjid.2017.03.006
- By:
- Publication type:
- Article
Cefepime–Taniborbactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.
- Published in:
- Drugs, 2024, v. 84, n. 10, p. 1219, doi. 10.1007/s40265-024-02082-9
- By:
- Publication type:
- Article
Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.
- Published in:
- Drugs, 2022, v. 82, n. 5, p. 533, doi. 10.1007/s40265-022-01688-1
- By:
- Publication type:
- Article
Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia.
- Published in:
- Drugs, 2021, v. 81, n. 2, p. 233, doi. 10.1007/s40265-020-01443-4
- By:
- Publication type:
- Article
Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent.
- Published in:
- Drugs, 2020, v. 80, n. 3, p. 285, doi. 10.1007/s40265-020-01257-4
- By:
- Publication type:
- Article
Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
- Published in:
- Drugs, 2019, v. 79, n. 3, p. 271, doi. 10.1007/s40265-019-1055-2
- By:
- Publication type:
- Article
Correction to: Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
- Published in:
- Drugs, 2018, v. 78, n. 7, p. 787, doi. 10.1007/s40265-018-0910-x
- By:
- Publication type:
- Article
Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
- Published in:
- Drugs, 2018, v. 78, n. 1, p. 65, doi. 10.1007/s40265-017-0851-9
- By:
- Publication type:
- Article
Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia.
- Published in:
- Drugs, 2016, v. 76, n. 18, p. 1737, doi. 10.1007/s40265-016-0667-z
- By:
- Publication type:
- Article
Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent.
- Published in:
- Drugs, 2016, v. 76, n. 5, p. 567, doi. 10.1007/s40265-016-0545-8
- By:
- Publication type:
- Article
Tedizolid: A Novel Oxazolidinone with Potent Activity Against Multidrug-Resistant Gram-Positive Pathogens.
- Published in:
- 2015
- By:
- Publication type:
- Journal Article
Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative Bacilli.
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative Bacilli.
- Published in:
- Drugs, 2014, v. 74, n. 1, p. 31, doi. 10.1007/s40265-013-0168-2
- By:
- Publication type:
- Article
Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor Combination.
- Published in:
- 2013
- By:
- Publication type:
- Journal Article
Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor Combination.
- Published in:
- Drugs, 2013, v. 73, n. 2, p. 159, doi. 10.1007/s40265-013-0013-7
- By:
- Publication type:
- Article
Activity of ceftolozane/tazobactam against Gram-negative isolates from patients with lower respiratory tract infections – SMART United States 2018–2019.
- Published in:
- BMC Microbiology, 2021, v. 21, n. 1, p. 1, doi. 10.1186/s12866-021-02135-z
- By:
- Publication type:
- Article
Emerging resistance among bacterial pathogens in the intensive care unit -- a European and North American Surveillance study (2000-2002).
- Published in:
- Annals of Clinical Microbiology & Antimicrobials, 2004, v. 3, p. 14, doi. 10.1186/1476-0711-3-14
- By:
- Publication type:
- Article
Prevalence and antimicrobial susceptibilities of bacteria isolated from blood cultures of hospitalized patients in the United States in 2002.
- Published in:
- Annals of Clinical Microbiology & Antimicrobials, 2004, v. 3, p. 7, doi. 10.1186/1476-0711-3-7
- By:
- Publication type:
- Article
Prevalence of antimicrobial resistance in bacteria isolated from central nervous system specimens as reported by U.S. hospital laboratories from 2000 to 2002.
- Published in:
- Annals of Clinical Microbiology & Antimicrobials, 2004, v. 3, p. 3, doi. 10.1186/1476-0711-3-3
- By:
- Publication type:
- Article
Tracking the implementation of NCCLS M100-S12 expanded-spectrum cephalosporin MIC breakpoints for nonmeningeal isolates of Streptococcus pneumoniae by clinical laboratories in the United States during 2002 and 2003.
- Published in:
- Annals of Clinical Microbiology & Antimicrobials, 2004, v. 3, p. 1, doi. 10.1186/1476-0711-3-1
- By:
- Publication type:
- Article
New Lipoglycopeptides: A Comparative Review of Dalbavancin, Oritavancin and Telavancin.
- Published in:
- Drugs, 2010, v. 70, n. 7, p. 859, doi. 10.2165/11534440-000000000-00000
- By:
- Publication type:
- Article